[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Société Algérienne de Formation et Recherche en Oncologie\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":119},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100634654","real-world-bicohort-observational-study-of-a-pertuzumab-biosimilar-in-the-treatment-of-breast-cancer-in-the-neoadjuvant-setting-and-in-first-line-metastatic-disease-100634654",false,"NCT07542496","Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease","PERTUREAL","Inclusion Criteria:\n\n* Age ≥ 19 years at the time of inclusion;\n* Histologically confirmed diagnosis of HER2-positive invasive breast cancer (IHC 3+ score or HER2 amplification by FISH\u002FCISH\u002FSISH);\n* Decision to initiate treatment with a pertuzumab biosimilar in the neoadjuvant setting (neoadjuvant cohort) or as first-line therapy in the metastatic setting (metastatic cohort), in accordance with local indications;\n* Treatment prescribed as part of routine clinical care (outside of a clinical trial);\n* Patient informed and having provided written informed consent.\n\nExclusion Criteria:\n\n* Treatment with pertuzumab in a therapeutic setting other than neoadjuvant or first-line metastatic (e.g., adjuvant, late recurrence beyond first-line, maintenance therapy alone, etc.);\n* Treatment administered as part of an interventional clinical trial;\n* History of severe allergy or known contraindication to pertuzumab;\n* Medical records unavailable or inability to ensure at least 6 months of minimal follow-up.","FEMALE","19 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to describe the real-world utilization patterns of a pertuzumab biosimilar and to evaluate its clinical outcomes in patients with breast cancer in both neoadjuvant and metastatic settings. It also aims to assess pathological complete response (pCR), disease-free survival (DFS) in the neoadjuvant cohort, progression-free survival (PFS) in the metastatic cohort, overall survival (OS), treatment response, and safety and tolerability (adverse events according to CTCAE) across both cohorts.",[24,25],"Breast Cancer","Her 2 Positive Breast Cancer",[27,28,29,30,31,24,32,33,34,35,36,37,38,39,40],"Algerian Study","Real-world data","Algeria","Biosimilar","Pertuzumab","Cancer","Breast cancer in Algerian patients","HER2-Positive Breast Cancer","Neoadjuvant Therapy","Anti-HER2 Therapy","Cohort Study","Non-Interventional Study","HER2-Targeted Therapy","Observational Study","RECRUITING","2026-04-14",{"date":44,"type":45},"2026-04-21","ACTUAL",{"date":47,"type":45},"2026-01-15",{"date":49,"type":20},"2027-01-15",{"name":51,"class":52},"Société Algérienne de Formation et Recherche en Oncologie","OTHER",2,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":61,"minAge":17,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":64,"conditions":65,"keywords":72,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100630230","study-of-the-epidemiological-clinical-diagnostic-and-therapeutic-characteristics-of-prostate-cancers-in-algeria-100630230","NCT07484971","Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria","CLIQQC","Inclusion Criteria:\n\n* Patients aged 19 years and older.\n* Diagnosis of prostate cancer confirmed histologically and\u002For biologically.\n* Patients followed in the participating oncology departments.\n* Written informed consent obtained.\n\nNon Inclusion Criteria:\n\n* Histological types other than carcinoma\n* Secondary tumors\n* Participation in an interventional study","MALE",{"count":63,"type":20},2000,"The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer.\n\nIt also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.",[66,67,68,69,70,71],"Prostate Cancer","Prostate Cancer (Diagnosis)","Prostate Cancer (Post Prostatectomy)","Prostate Cancer Patients Treated by Radiotherapy","Prostate Cancer Metastatic","Prostate Cancer (Adenocarcinoma)",[73,74,66,75,40,76,77,78,79,80,81,82,28,29,27],"oncology","patient outcome","Prostate Cancer in Algerian patients","Retrospective data","Treatment strategies","Diagnostic approaches","Clinical characteristics","Epidemiological data","Demographic data","Cross-sectional study",{"date":84,"type":45},"2026-04-17",{"date":86,"type":45},"2025-07-21",{"date":88,"type":20},"2026-07-21",{"name":51,"class":52},24,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":98,"minAge":17,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":100,"conditions":101,"keywords":105,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},"100629933","study-of-the-epidemiological-clinical-diagnostic-and-therapeutic-characteristics-of-gastric-cancers-in-algeria-100629933","NCT07481110","Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria","ECLIPSE-CG","Inclusion Criteria:\n\n* Patients aged 19 years and older\n* Histologically confirmed diagnosis of gastric cancer\n* Patients followed in the participating oncology departments\n* Informed consent obtained\n\nNon Inclusion Criteria:\n\n* Histological types other than carcinoma (e.g., GIST, lymphoma, sarcoma, etc.).\n* Secondary gastric tumors\n* Participation in an interventional study","ALL",{"count":19,"type":20},"The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with gastric cancer.\n\nIt also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.",[102,103,104],"Gastric Cancer","Gastric (Stomach) Cancer","Gastric Cancer (Diagnosis)",[102,106,107,108,109,76,77,78,79,80,81,82,28,29,27],"Gastric cancer in Algerian patients","Observational study","Patient outcomes","Oncology","2026-03-25",{"date":112,"type":45},"2026-03-27",{"date":114,"type":45},"2025-08-05",{"date":116,"type":20},"2026-08-05",{"name":51,"class":52},15,""]